You have a biological product that works. You have field data, maybe grower testimonials, maybe replicated trial results. But when a technical buyer, an agronomist, or a potential partner asks you to explain the mechanism — what your product is actually doing inside the plant — what do you say?

If the answer is "we're still working on that," you're not alone. And you're not behind. But you might be closer to having that answer than you think.

Join Dr. Layne Ellen Harris, founder of Foresight Agronomics, for a practical, candid overview of transcriptomic analysis and what it actually means for biological product development. In this session, we'll cover:

• What transcriptomic analysis is — and what it isn't (including how it's different from genomics, metabolomics, and the other "-omics" you've heard about)

• What kinds of questions it can answer: application timing, rate optimization, off-target effects, mechanism of action, and more

• How the process actually works, from trial design through final report

• Who it's most useful for — and how to know if your product is a good candidate

• What Foresight's 2026 group study offerings look like for companies ready to move forward

This is a real conversation about a tool that the biological industry is only beginning to use well — and why that matters for the companies building products in this space.

Register now and you'll receive Is Your Biological Ready for Transcriptomic Analysis? — a free checklist to help you assess where your product stands and whether a transcriptomic study belongs in your 2026 R&D plan.

Spots are limited. Enrollment for 2026 studies closes April 15.